ISPOR 18th ANNUAL EUROPEAN CONGRESS FEATURES WORKSHOP ON OPTIMIZING PATIENT INVOLVEMENT IN PAYER HEALTH CARE DECISIONS

Published Nov 10, 2015

WORKSHOP PRESENTS WORK BY THE ISPOR EUROPEAN PATIENT REPRESENTATIVES ROUNDTABLE 

Milan, Italy—November 10, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress Workshop 12 focused on the issue of, “Optimizing Patient Involvement in Payer Health Care Decisions to Access New Therapies.” This workshop was held this morning at the MiCo – Milano Congressi in Milan, Italy. The workshop was led by discussion leaders: - Don Husereau, Senior Associate, Epidemiology and Community Medicine, University of Ottawa, Canada - Nicola Bedlington, Director, European Patients' Forum, Brussels, Belgium - Michael Barry, MD, PhD, Clinical Director, National Centre for Pharmacoeconomics, Dublin, Ireland - Veronica Foote, BA, Head of Patient Relations & External Communications, Novartis Oncology Europe, Surrey, UK As patients are becoming increasingly involved with the use of evidence to support payer decisions for new therapies and technologies, interest in patients’ participation in health care decision making is growing. The workshop explored how all stakeholders including patients, HTA, payers, and industry can work together to optimize patient involvement in decisions, based on work conducted by the ISPOR European Patient Representatives Roundtable. Released presentations from the ISPOR 18th Annual European Congress are available at http://www.ispor.org/Event/ReleasedPresentations/2015Milan. ISPOR’s 18th Annual European Congress may be followed on social media using the hashtag #ISPORMilan.

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×